Brought to you by 
Amersham markets reagents for Molecular Staging's RCAT
18 Jul 2000
Executive Summary
Nycomed Amersham division Amersham Pharmacia Biotech has received an exclusive license to market reagents for all research procedures using Molecular Staging's (diagnostics for detection, staging, and prognosis of disease) Rolling Circle Amplification Technology (RCAT).
Deal Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amersham markets reagents for Molecular Staging's RCAT
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice